Researchers also found that in the third of study participants whose ribavirin
dosage was reduced as a result of anemia, cure rates actually improved to as high as 52 percent, whereas in those whose ribavirin dose stayed the same, cure rates were lower, at 37 percent."
"However, the new study, he says, shows that “we now have evidence that we can safely use less aggressive dosages without compromising a patient’s chances for long-term recovery.